Milestone Pharmaceuticals Inc

NASDAQ MIST

Data sourced from

and

Daily

Download Data

Milestone Pharmaceuticals Inc Enterprise Value to EBITDA (EV/EBITDA) on June 03, 2024: -0.79

Milestone Pharmaceuticals Inc Enterprise Value to EBITDA (EV/EBITDA) is -0.79 on June 03, 2024, a 56.99% change year over year. The EV/EBITDA ratio compares a company's enterprise value to its EBITDA. It provides insight into the company's valuation relative to its earnings and is commonly used in comparing the relative value of different companies within an industry. A lower ratio suggests a potentially more favorable valuation.

Milestone Pharmaceuticals Inc 52-week high Enterprise Value to EBITDA (EV/EBITDA) is 0.27 on March 14, 2024, which is 133.87% above the current Enterprise Value to EBITDA (EV/EBITDA).
Milestone Pharmaceuticals Inc 52-week low Enterprise Value to EBITDA (EV/EBITDA) is -2,382.21 on August 10, 2023, which is -301,046.83% below the current Enterprise Value to EBITDA (EV/EBITDA).
Milestone Pharmaceuticals Inc average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is -20.03.

NASDAQ: MIST

Milestone Pharmaceuticals Inc

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard, Montreal, QC, Canada, H4M 2X6
Employees	47
Sector	Healthcare
Industry	Biotechnology

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends